Why Novo Is Paying Billions for a Weight-Loss Pill
Novo Nordisk agreed to pay up to $2.6 billion for rights to an experimental weight-loss pill from Jiangsu Hengrui Pharmaceuticals. The deal was reported 29 September 2026. It starts with $300 million paid at signing, according to Reuters and Wall Street Journal. The rest is paid only if testing, approval and sales goals are met.
The pill would be taken by mouth once a week. It copies two natural gut signals, GLP-1 and GIP, that cut hunger and control blood sugar. The license is exclusive to Novo Nordisk and was signed in September 2026, according to Novo Nordisk.
Jiangsu Hengrui Pharmaceuticals is the company supplying the pill, according to Reuters. Four days earlier, on 25 September 2026, Novo Nordisk struck a separate €1.17 billion deal with Nanexa for injection technology, according to Reuters.
Earlier, Novo Nordisk and Orbis signed a deal worth up to $1.4 billion to develop drugs you swallow. It was reported 17 September 2026. Orbis gets upfront money now, milestone money later if trials succeed, plus tiered royalties, a sales share that grows with sales, according to Reuters. Think of it like a house deposit, with the rest tied to finished work.
Novo Nordisk plans to set out new long-term goals, called Strategic Aspirations, at its investor day on 21 September 2026, according to Novo Nordisk Annual Report.
The broader context here is payment in steps, not one big cheque. Three deals closed in one month. Two are for pills. One is for shots. Partners share the risk if drugs fail.
Looking at what this means for future medicines, Novo Nordisk is keeping two paths open. Hengrui brings the weekly pill formula. Orbis brings more pill research. Nanexa brings shot know-how. Novo Nordisk handles the final large trials.
In my view, the order and cost matter for ordinary savers and investors. The Nanexa and Orbis deals came first, then Hengrui, around the update to long-term goals. The question is how paying outside firms fits with lab spending, profits and sales shares if several drugs move ahead. Watch what Novo says about length of exclusivity, territory, who runs testing, and when payments fall due: Phase 2, filing for approval and first sale.
